Kaminski, Rafal
Chen, Yilan
Salkind, Julian
Bella, Ramona
Young, Won-bin
Ferrante, Pasquale
Karn, Jonathan
Malcolm, Thomas
Hu, Wenhui
Khalili, Kamel
Article History
Received: 9 June 2016
Accepted: 20 July 2016
First Online: 16 August 2016
Competing interests
: K.K., W.H., R.K. and T.M. are named inventors on patents that cover the viral gene editing technology that is the subject of this manuscript. In addition to the foregoing interests, K.K. is a co-founder, board member, scientific advisor and holds equity in Excision Biotherapeutics, a biotech start-up which has licensed the viral gene editing technology from Temple University for commercial development and clinical trials. T.M. is chief executive officer, chairman of the board, co-founder and holds equity in Excision Biotherapeutics. The authors declare that this work was produced solely by the authors and that no other individuals or entities influenced any aspects of the work including, but not limited to, the study conception and design; data acquisition, analysis and interpretation; and writing of the manuscript.